Drummond, M.

price health health technology assessment reference pricing reference assessment technology insulin pricing reimbursement patient policy germany reference price netherland statin health technology assessments treatment value country indication difference cluster kingdom analogue institute type 2 diabetes manufacturer iqwig reimbursement status diabetes ezetimibe glargine atorvastatin pharmaceutical decision ef ficiency appraisal insulin analogues insulin glargine group money sweden drummond system study scheme level rosuvastatin cost-effectiveness product health care agent status simvastatin london detemir atypical patient co-payments result netherlands swedena patient subgroups quality table fi rst exchange excellence reimbursement limit glulisine therapy lispro pharmacy prices health economics co-payment arthritis example jonsson amount evaluation approach